Probiotics – between offer and confirmation

The significant increase (35-67%) of sales of probiotics requires an analysis of the justification for this use in relation to the evidence supported studies. EFSA (European Food Safety Authority) supports their efficiency potential, but warns that they are insufficient proven cause-effect relationship yet. Recommendation of these preparations are made for: gastroenteritis, diarrhea associated with antibiotics, lactose intolerance, atopy in children, atopic dermatitis, inflammatory bowel disease, irritable bowel syndrome, necrotizing enterocolitis, bacterial vaginosis, as an adjuvant in dyslipidemia, gastroduodenitis with Helicobacter pylori. According to records of current research results they are needed new data from the main regulatory agencies (FDA and EFSA) to guide treatment recommendations for probiotics.